Microencapsulated, cyp2b1-transfected cells activating ifosfamide at the site of the tumor: The magic bullets of the 21st century

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 49, Issue 7, 2002, Pages S21-S24

  Löhr, Matthias ^a   Hummel, Frank ^a   Faulmann, Grit ^a   Ringel, Jörg ^a   Saller, Robert ^b   Hain, Johannes ^b   Günzburg, Walter H ^c   Salmons, Brian ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d Austrianova Biotherapeutics   (Austria)

Author keywords

CYP2B1 transfected cells; Ifosfamide

Indexed keywords

CYTOCHROME P450 2B1; CYTOSTATIC AGENT; IFOSFAMIDE; RESORUFIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER LOCALIZATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROCAPSULE; MICROENCAPSULATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS; CYTOCHROME P-450 CYP2B1; DRUG COMPOUNDING; GENETIC ENGINEERING; HUMANS; IFOSFAMIDE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; SWINE; TRANSFECTION;

EID: 0036244747     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: A phase II study
2. Ifosfamide treatment as a 10-day continuous intravenous infusion
3. Ifosfamide chemotherapy for pancreatic carcinoma
4. Ifosfamide in advanced pancreatic cancer
5. Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas
6. An investigational new drug treatment program for patients with gemcitabine
7. Microencapsulated islets as bioartificial endocrine pancreas
8. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases
9. Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly(L)lysine-alginate (APA) membrane following allogenic transplantation
10. Development of cellulose sulphate-based polyelectrolyte complex microcapsules for medical applications
11. Microencapsulated, cell mediated treatment of inoperable pancreatic carcinoma
12. Combined chemotherapy of murine mammary tumors by local activation of prodrugs ifosfamide and 5-fluorocytosine
13. Molecular basis for a functionally unique cytochrome P450IIB1 variant
14. Targeted chemotherapy by encapsulating cells engineered to deliver CYP2B1, an ifosfamide activating cytochrome P450 gene
15. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloracetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy
16. Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy
17. Transforming growth factor-beta 1 induces desmoplasia in an experimental model of human pancreatic carcinoma
18. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors
19. Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins
20. Microencapsulation of genetically engineered cells for cancer therapy
21. Intraarterial instillation of microencapsulated cells in the pancreatic arteries in pig
22. Cell therapy using microencapsulated 293 cells transfected a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma. A phase I-study
23. Paul Ehrlich and his magic bullets - Revisited
24. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer
25. Adenovirus-mediated gene transfer into an experimental pancreatic tumour
26. Ribozyme as an approach for growth suppression of human pancreatic cancer
27. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer
28. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo
29. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity
30. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells
31. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies